Randomized Controlled Trial of Etodolac versus Combination of Etodolac and Eperisone in Patients of Knee Osteoarthritis

Table 3

Secondary efficacy variable assessment across time in both the groups.

Efficacy variables; (Mean ± SD)	Visits	Etodolac group; (𝑛=30)	Etodolac + eperisone group; (𝑛=30)	Difference between the groups; (𝑃 value)
Joint tenderness score	Baseline; At 8 weeks	2.63±0.49; 1.43±0.80	2.50±0.51; 1.07±0.65	0.086
Swelling score	Baseline; At 8 weeks	1.87±0.68; 1.07±0.25	1.90±0.84; 1.00±0.00	0.107
Erythema score	Baseline; At 8 weeks	1.80±0.66; 1.07±0.25	1.87±0.82; 1.03±0.18	0.232
Pain on movement score	Baseline; At 8 weeks	2.43±0.57; 1.23±0.43	2.37±0.56; 1.03±0.48	0.097
Functional capacity score	Baseline; At 8 weeks	2.57±0.57; 1.27±0.52	2.43±0.50; 1.10±0.31	0.107
Overall arthritic condition score	Baseline; At 8 weeks	3.53±0.57; 1.70±0.70	3.47±0.51; 1.50±0.57	0.135